Literature DB >> 16646072

ARLTS1 variants and melanoma risk.

Bernd Frank1, Peter Meyer, Melanie Barbara Boettger, Kari Hemminki, Henrike Stapelmann, Andreas Gast, Christina Schmitt, Rajiv Kumar, Consolato Sergi, Barbara Burwinkel.   

Abstract

Variants in the tumor suppressor gene ARLTS1 (ADP-ribosylation factor-like tumor-suppressor gene 1) have been shown to influence familial cancer risk. Both Cys148Arg and Trp149Stop were associated with an increased risk of familial or high-risk familial breast cancer, respectively. We studied the impact of these gene variants on melanoma risk, investigating 351 melanoma patients and 804 control subjects. While ARLTS1 Trp149Stop did not influence melanoma risk (OR = 0.83, 95% CI = 0.37-1.88, p = 0.65), Cys148Arg revealed a statistically significant association with an increased risk for heterozygous carriers (OR = 1.43, 95% CI = 1.05-1.95, p = 0.02). An additional risk enhancement, though statistically non-significant, was observed in individuals with multiple melanomas (OR = 2.33, 95% CI = 0.87-6.26, p = 0.08). Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16646072     DOI: 10.1002/ijc.22008

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.

Authors:  Elif Akisik; Hulya Yazici; Nejat Dalay
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

2.  ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer.

Authors:  Sanna Siltanen; Kirsi Syrjäkoski; Rainer Fagerholm; Tarja Ikonen; Peter Lipman; Jacob Mallott; Kaija Holli; Teuvo L J Tammela; Heikki J Järvinen; Jukka-Pekka Mecklin; Kristiina Aittomäki; Carl Blomqvist; Joan E Bailey-Wilson; Heli Nevanlinna; Lauri A Aaltonen; Johanna Schleutker; Pia Vahteristo
Journal:  Eur J Hum Genet       Date:  2008-03-12       Impact factor: 4.246

3.  Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.

Authors:  Sanna Siltanen; Tiina Wahlfors; Martin Schindler; Outi R Saramäki; John Patrick Mpindi; Leena Latonen; Robert L Vessella; Teuvo L J Tammela; Olli Kallioniemi; Tapio Visakorpi; Johanna Schleutker
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

Review 4.  ARLTS1 polymorphism is associated with an increased risk of familial cancer: evidence from a meta-analysis.

Authors:  Yan Jiang; Chen-Yang Zhao; Li-Chun Cheng; Bing Xu; Hui-Yi Lv
Journal:  Hered Cancer Clin Pract       Date:  2017-06-13       Impact factor: 2.857

Review 5.  The Role of ARF Family Proteins and Their Regulators and Effectors in Cancer Progression: A Therapeutic Perspective.

Authors:  Cristina Casalou; Andreia Ferreira; Duarte C Barral
Journal:  Front Cell Dev Biol       Date:  2020-04-21

6.  ARLTS1 polymorphisms and basal cell carcinoma of the skin.

Authors:  Xuchen Li; Andreas Gast; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Kari Hemminki; Rajiv Kumar
Journal:  Hered Cancer Clin Pract       Date:  2007-03-15       Impact factor: 2.857

7.  ARLTS1 and prostate cancer risk--analysis of expression and regulation.

Authors:  Sanna Siltanen; Daniel Fischer; Tommi Rantapero; Virpi Laitinen; John Patrick Mpindi; Olli Kallioniemi; Tiina Wahlfors; Johanna Schleutker
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

8.  Mosaic 13q14 deletions in peripheral leukocytes of non-hematologic cancer cases and healthy controls.

Authors:  Mitchell J Machiela; Weiyin Zhou; Neil Caporaso; Michael Dean; Susan M Gapstur; Lynn Goldin; Victoria L Stevens; Meredith Yeager; Stephen J Chanock
Journal:  J Hum Genet       Date:  2016-01-14       Impact factor: 3.172

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.